Business | Biotechnology

Seedy business

It’s eat or be eaten for the firms that make seeds and chemicals for farmers

|NEW YORK

WHEN DuPont and Dow Chemical agreed to merge in December, the $130 billion deal seemed to be a prime example of American managers’ ruthless pursuit of shareholder value and dedication to building monopoly positions. The two chemicals firms, with a combined 300-odd years under their belts, had both been beaten up by activist investors in the 20 months or so leading up to the deal.

Partly in response, the companies said they would combine and then split into three new firms, focused on agriculture, speciality products (used, for example, in electronics), and materials (used in plastics). Huge cost cuts are planned when the deal closes, supposedly later this year. The unspoken message to investors is that the three new firms, with higher market shares, will also be able to raise prices.

This article appeared in the Business section of the print edition under the headline "Seedy business"

When the drugs don’t work: The rise of antibiotic resistance

From the May 21st 2016 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Business

Can biotech startups upstage Eli Lilly and Novo Nordisk?

Smaller drugmakers are enjoying a revival

How to handle populists: a CEO’s survival guide

Western businesses are learning to live with volatile electoral politics around the world


Will war snuff out the Gulf’s global business ambitions?

Companies far and wide are feeling the effects of the conflict